Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Amrita Krishnan; Ajay K. Nooka; Ajai Chari; Alfred L. Garfall; Thomas G. Martin; Sandhya Nair; Xiwu Lin; Keqin Qi; Anil Londhe; Lixia Pei; Eric Ammann; Rachel Kobos; Jennifer Smit; Trilok Parekh; Alexander Marshall; Mary Slavcev; Saad Z. Usmani

doi:10.57264/cer-2022-0186

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Amrita Krishnan, Ajay K. Nooka, Ajai Chari, Alfred L. Garfall, Thomas G. Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Saad Z. Usmani

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59– 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

Original language	English
Article number	e220186
Journal	Journal of Comparative Effectiveness Research
Volume	12
Issue number	6
DOIs	https://doi.org/10.57264/cer-2022-0186
State	Published - 2023

Keywords

B-cell maturation antigen
MajesTEC-1
bispecific antibody
comparative effectiveness
indirect treatment comparison

Access to Document

10.57264/cer-2022-0186

Cite this

Krishnan, A., Nooka, A. K., Chari, A., Garfall, A. L., Martin, T. G., Nair, S., Lin, X., Qi, K., Londhe, A., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Marshall, A., Slavcev, M., & Usmani, S. Z. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research, 12(6), Article e220186. https://doi.org/10.57264/cer-2022-0186

@article{35ac82f4dd454d378e3e1409d9fd4910,

title = "Teclistamab versus real-world physician{\textquoteright}s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma",

abstract = "We compared the effectiveness of teclistamab versus real-world physician{\textquoteright}s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59– 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.",

keywords = "B-cell maturation antigen, MajesTEC-1, bispecific antibody, comparative effectiveness, indirect treatment comparison",

author = "Amrita Krishnan and Nooka, {Ajay K.} and Ajai Chari and Garfall, {Alfred L.} and Martin, {Thomas G.} and Sandhya Nair and Xiwu Lin and Keqin Qi and Anil Londhe and Lixia Pei and Eric Ammann and Rachel Kobos and Jennifer Smit and Trilok Parekh and Alexander Marshall and Mary Slavcev and Usmani, {Saad Z.}",

note = "Publisher Copyright: {\^A}{\textcopyright} 2023 Janssen Global Services.",

year = "2023",

doi = "10.57264/cer-2022-0186",

language = "English",

volume = "12",

journal = "Journal of Comparative Effectiveness Research",

issn = "2042-6305",

publisher = "Becaris Publishing Ltd",

number = "6",

}

Krishnan, A, Nooka, AK, Chari, A, Garfall, AL, Martin, TG, Nair, S, Lin, X, Qi, K, Londhe, A, Pei, L, Ammann, E, Kobos, R, Smit, J, Parekh, T, Marshall, A, Slavcev, M & Usmani, SZ 2023, 'Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma', Journal of Comparative Effectiveness Research, vol. 12, no. 6, e220186. https://doi.org/10.57264/cer-2022-0186

TY - JOUR

T1 - Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

AU - Krishnan, Amrita

AU - Nooka, Ajay K.

AU - Chari, Ajai

AU - Garfall, Alfred L.

AU - Martin, Thomas G.

AU - Nair, Sandhya

AU - Lin, Xiwu

AU - Qi, Keqin

AU - Londhe, Anil

AU - Pei, Lixia

AU - Ammann, Eric

AU - Kobos, Rachel

AU - Smit, Jennifer

AU - Parekh, Trilok

AU - Marshall, Alexander

AU - Slavcev, Mary

AU - Usmani, Saad Z.

PY - 2023

Y1 - 2023

N2 - We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59– 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

AB - We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59– 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

KW - B-cell maturation antigen

KW - MajesTEC-1

KW - bispecific antibody

KW - comparative effectiveness

KW - indirect treatment comparison

UR - http://www.scopus.com/inward/record.url?scp=85160966155&partnerID=8YFLogxK

U2 - 10.57264/cer-2022-0186

DO - 10.57264/cer-2022-0186

M3 - Article

C2 - 37114426

AN - SCOPUS:85160966155

SN - 2042-6305

VL - 12

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

IS - 6

M1 - e220186

ER -

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Abstract

Keywords

Access to Document

Fingerprint

Cite this